Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy
Praxis Precision Medicines, Inc. (PRAX)
Company Research
Source: GlobeNewswire
Elsunersen demonstrated placebo-adjusted seizure reduction from baseline of 77% (p=0.015) 71% of elsunersen-treated patients achieved 50% seizure reduction by period 6, with sustained benefit observed in the open-label extension for up to one year 100% of elsunersen patients - and none on placebo - had additional improvements, including sleep, motor function, muscle tone and attention No treatment-emergent or serious adverse events related to study drug reported BOSTON, April 06, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced positive topline results from the EMBRAVE Part A trial of elsunersen in pediatric patients with early-seizure onset SCN2A developmental and epileptic encephalopathy (DEE). “We are thrilled to see the remarkable, consistent results from EMBRAVE Part A, showing 77% reduction in monthly seizures and disease mod
Show less
Read more
Impact Snapshot
Event Time:
PRAX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PRAX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PRAX alerts
High impacting Praxis Precision Medicines, Inc. news events
Weekly update
A roundup of the hottest topics
PRAX
News
- Praxis Precision Medicines (PRAX) had its "buy" rating reaffirmed by Deutsche Bank Aktiengesellschaft.MarketBeat
- Praxis Precision Medicines (PRAX) had its "buy" rating reaffirmed by Needham & Company LLC. They now have a $510.00 price target on the stock.MarketBeat
- Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential TremorGlobeNewswire
- Praxis to Showcase Essential3, the First Positive Phase 3 Program in Essential Tremor, at AAN 2026GlobeNewswire
- Praxis Precision Medicines (PRAX) was upgraded by Raymond James Financial, Inc. to "strong-buy".MarketBeat
PRAX
Earnings
- 2/19/26 - Miss
PRAX
Sec Filings
- 4/14/26 - Form 8-K
- 4/6/26 - Form 8-K
- 3/27/26 - Form SCHEDULE
- PRAX's page on the SEC website